Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis
Metastatic or recurrent tumors are the primary cause of cancer-related death. For prostate cancer, patients diagnosed with local disease have a 99% 5-year survival rate; however, this 5-year survival rate drops to 28% in patients with metastatic disease. This dramatic decline in survival has driven...
Saved in:
Main Authors: | Koran S. Harris (Author), Bethany A. Kerr (Author) |
---|---|
Format: | Book |
Published: |
Hindawi Limited,
2017-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
GDF15 propeptide promotes bone metastasis of castration-resistant prostate cancer by augmenting the bone microenvironment
by: Gaku Yamamichi, et al.
Published: (2024) -
Predictive factors for bone metastasis in patients with prostate cancer
by: Reydienis Ricardo Infante Cedeño, et al.
Published: (2023) -
The Role of Adipose-Derived Stem Cells in Breast Cancer Progression and Metastasis
by: Riccardo Schweizer, et al.
Published: (2015) -
Bone-targeted nanoplatform enables efficient modulation of bone tumor microenvironment for prostate cancer bone metastasis treatment
by: Xiangyu Zhang, et al.
Published: (2022) -
Overcoming Therapeutic Resistance of Bone Sarcomas: Overview of the Molecular Mechanisms and Therapeutic Targets for Bone Sarcoma Stem Cells
by: Tomohiro Fujiwara, et al.
Published: (2016)